To SAMHSA / NIDA / NIMH

Request:

Requesting any and all records, internal communications, contracts, or research proposals relating to the use of GLP-1 receptor agonists (including semaglutide, liraglutide, exenatide, dulaglutide, and related compounds) in the context of addiction recovery, relapse prevention, or substance use disorder treatment, from 2019 to present.

This includes:
	•	Pilot programs or population-level trials involving GLP-1 compounds and recovery cohorts
	•	Vendor contracts for drug distribution or monitoring technologies
	•	Ethical reviews regarding nonconsensual or covert administration of GLP-1 drugs under recovery frameworks
	•	Reports, audits, or oversight documents evaluating outcomes beyond officially approved indications

Keywords: GLP-1, semaglutide, liraglutide, dulaglutide, exenatide, Ozempic, Wegovy, Trulicity, addiction recovery, relapse prevention, covert dosing

⸻ 

To CDC / FDA / BARDA / NIH (NIAID, NIMH, NIDA)

Request:
Requesting any and all records, internal communications, research proposals, contracts, or vendor agreements relating to the administration of GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, and exenatide) under the framework of Covid-19 vaccination, pandemic countermeasures, or recovery programs, from 2019 to present.

This includes:
	•	Pilot studies or mass-trial designs involving GLP-1 drugs delivered in conjunction with, or under the umbrella of, Covid vaccination campaigns
	•	Contracts with pharmaceutical manufacturers or logistics providers linking GLP-1 compounds to vaccine distribution channels
	•	Adverse event monitoring reports or internal analyses cross-referencing vaccine recipients with GLP-1 exposure outcomes
	•	Ethical review board discussions regarding nonconsensual or covert administration of GLP-1 compounds during Covid countermeasure efforts
	•	Communications on addiction recovery or substance use framing as a context for GLP-1 distribution tied to Covid vaccine programs

Keywords: GLP-1, semaglutide, liraglutide, dulaglutide, exenatide, Ozempic, Wegovy, Trulicity, Covid vaccine, pandemic countermeasure, covert dosing, addiction recovery, relapse prevention




